MA41643B1 - Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton - Google Patents

Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Info

Publication number
MA41643B1
MA41643B1 MA41643A MA41643A MA41643B1 MA 41643 B1 MA41643 B1 MA 41643B1 MA 41643 A MA41643 A MA 41643A MA 41643 A MA41643 A MA 41643A MA 41643 B1 MA41643 B1 MA 41643B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
pharmaceutical formulations
bruton
kinase inhibitor
conditions
Prior art date
Application number
MA41643A
Other languages
English (en)
Other versions
MA41643A (fr
Inventor
Robert Kuehl
Harisha Atluri
Ching Chong
Heow Tan
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Priority claimed from PCT/US2016/020467 external-priority patent/WO2016141068A1/fr
Publication of MA41643A publication Critical patent/MA41643A/fr
Publication of MA41643B1 publication Critical patent/MA41643B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques d'un inhibiteur de la tyrosine kinase de bruton (btk), le 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo [3,4-d] pyrimidin-1-yl) pipéridin-1-yl) prop-2-én-1-one. L'invention concerne des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou de pathologies auto-immunes, de maladies ou de pathologies hétéro-immunes, du cancer, y compris du lymphome, et de maladies ou de pathologies inflammatoires.
MA41643A 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton MA41643B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127717P 2015-03-03 2015-03-03
PCT/US2016/020467 WO2016141068A1 (fr) 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Publications (2)

Publication Number Publication Date
MA41643A MA41643A (fr) 2018-01-09
MA41643B1 true MA41643B1 (fr) 2024-02-29

Family

ID=59254075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41643A MA41643B1 (fr) 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Country Status (2)

Country Link
AR (1) AR103832A1 (fr)
MA (1) MA41643B1 (fr)

Also Published As

Publication number Publication date
AR103832A1 (es) 2017-06-07
MA41643A (fr) 2018-01-09

Similar Documents

Publication Publication Date Title
MA41654B2 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
MX394784B (es) Composiciones farmacéuticas de un inhibidor de tirosina cinasa de bruton.
PH12020552065A1 (en) Ibrutinib combination therapy
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
HK1249736A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA38961A1 (fr) Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
MX394327B (es) Sintesis de un inhibidor de tirosina quinasa de bruton
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
AR103832A1 (es) Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton
FR2930156B1 (fr) Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.